Alpha 2.0
Login Register
» Authors » H Quentmeier

H Quentmeier

Explore the profile of H Quentmeier including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 64
Citations 1114
Followers 0
Related Specialties
Hematology
Oncology
Allergy & Immunology
Top 10 Co-Authors
H G Drexler
M Zaborski
R A F MacLeod
S M Gignac
C C Uphoff
C Meyer
Z B Hu
S Nagel
P F Muhlradt
R A MacLEOD
Published In
Leukemia
Leuk Lymphoma
Leuk Res
Br J Haematol
Infect Immun
Affiliations
Soon will be listed here.
Recent Articles
1.
Acid Phosphatase Isoenzyme Profiles in Acute and Chronic Leukemias
Gignac S, Quentmeier H, Brauer S, Hoffbrand A, Drexler H
Leuk Lymphoma . 2016 Jul; 5(5-6):293-303. PMID: 27463338
We analyzed the acid phosphatase (AcP) isoenzyme profiles of normal and malignant hematopoietic cells using isoelectric focusing followed by diazo staining. Reproducibly defined bands and band complexes could be identified...
2.
Chromosome 11q23 aberrations activating FOXR1 in B-cell lymphoma
Pommerenke C, Hauer V, Zaborski M, MacLeod R, Nagel S, Amini R, et al.
Blood Cancer J . 2016 Jun; 6:e433. PMID: 27284737
No abstract available.
3.
MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling
Kollmann K, Nangalia J, Warsch W, Quentmeier H, Bench A, Boyd E, et al.
Leukemia . 2014 Sep; 29(2):494-7. PMID: 25249012
No abstract available.
4.
Purification of an autocatalytic protein-glycosylating enzyme from cell suspensions of Daucus carota L
Quentmeier H, Ingold E, Seitz H
Planta . 2013 Nov; 171(4):483-8. PMID: 24225709
A glycosyltransferase was identified in the 174 000 · g membrane pellet and the supernatant from extracts of cell suspensions of Daucus carota L. The enzyme from the supernatant was...
5.
U-2932: two clones in one cell line, a tool for the study of clonal evolution
Quentmeier H, Amini R, Berglund M, Dirks W, Ehrentraut S, Geffers R, et al.
Leukemia . 2013 Jan; 27(5):1155-64. PMID: 23295736
Genetic heterogeneity is common in tumors, explicable by the development of subclones with distinct genetic and epigenetic alterations. We describe an in vitro model for cancer heterogeneity, comprising the diffuse...
6.
The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations
Tiacci E, Spanhol-Rosseto A, Martelli M, Pasqualucci L, Quentmeier H, Grossmann V, et al.
Leukemia . 2011 Sep; 26(3):554-7. PMID: 21904384
No abstract available.
7.
A novel ABL1 fusion to the SH2 containing inositol phosphatase-1 (SHIP1) in acute lymphoblastic leukemia (ALL)
Kakadia P, Tizazu B, Mellert G, Harbott J, Rottgers S, Quentmeier H, et al.
Leukemia . 2011 Jun; 25(10):1645-9. PMID: 21625237
No abstract available.
8.
EZH2 Y641 mutations in follicular lymphoma
Bodor C, ORiain C, Wrench D, Matthews J, Iyengar S, Tayyib H, et al.
Leukemia . 2011 Jan; 25(4):726-9. PMID: 21233829
No abstract available.
9.
Hypermethylation of Death-Associated Protein Kinase 1 differentiates natural killer cell lines from cell lines derived from T-acute lymphoblastic leukemia
Rohrs S, Romani J, Zaborski M, Drexler H, Quentmeier H
Leukemia . 2009 Feb; 23(6):1174-6. PMID: 19212339
No abstract available.
10.
SOCS2: inhibitor of JAK2V617F-mediated signal transduction
Quentmeier H, Geffers R, Jost E, MacLeod R, Nagel S, Rohrs S, et al.
Leukemia . 2008 Sep; 22(12):2169-75. PMID: 18769447
Janus kinase 2 (JAK2)V617F-activating mutations (JAK2mu) occur in myeloproliferative disorders (MPDs) and myelodysplastic syndromes (MDSs). Cell lines MB-02, MUTZ-8, SET-2 and UKE-1 carry JAK2V617F and derive from patients with MPD/MDS...